Company Valuation: Thiogenesis Therapeutics, Corp.

Data adjusted to current consolidation scope
Fiscal Period: December 2022 2023 2024 2025
Market Cap 1 22.54 33.43 27.61 33.69
Change - 48.3% -17.4% 22.03%
Enterprise Value (EV) 1 16.34 26.35 23.76 32.08
Change - 61.23% -9.83% 34.99%
P/E -3.74x -5.8x -8.65x -4.25x
PBR 3.77x 6.04x 8.06x 58.7x
PEG -0x 0.3x 0.2x -0x
Capitalization / Revenue - - - -
EV / Revenue - - - -
EV / EBITDA - - - -
EV / EBIT -8.14x -5.06x -6.64x -4.34x
EV / FCF - - - -
FCF Yield - - - -
Dividend per Share 3 - - - -
Rate of return - - - -
EPS 3 -0.1552 -0.1294 -0.0693 -0.1528
Distribution rate - - - -
Net sales - - - -
EBITDA - - - -
EBIT 1 -2.009 -5.206 -3.579 -7.395
Net income 1 -3.924 -5.063 -3.146 -7.426
Net Debt 1 -6.196 -7.076 -3.848 -1.616
Reference price 3 0.5800 0.7500 0.6000 0.6500
Nbr of stocks (in thousands) 38,862 44,571 46,017 51,836
Announcement Date 4/28/23 4/29/24 4/25/25 4/30/26
1CAD in Million2USD in Million3CAD
Estimates


P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
20.5x7.33x14.72x1.45% 70.61B
27.46x7.51x23.56x0.05% 51.01B
33.37x6x17.96x0.97% 48.1B
33.47x3.25x14.03x-.--% 42.78B
-19.64x203.45x-20.92x-.--% 40.67B
46.95x5.34x29.33x-.--% 40.3B
27.18x7.73x20.09x0.42% 30.59B
32.53x6.94x18.03x-.--% 28.16B
-14.69x5.97x-7.21x-.--% 24.36B
Average 20.79x 28.17x 12.18x 0.32% 41.84B
Weighted average by Cap. 22.22x 27.61x 13.23x 0.44%

Y-o-Y evolution of P/E

Valuation ratios - P/E - Thiogenesis Therapeutics, Corp.

Historical PBR trend

Valuation ratios - PBR - Thiogenesis Therapeutics, Corp.

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - Thiogenesis Therapeutics, Corp.

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - Thiogenesis Therapeutics, Corp.

  1. Stock Market
  2. Stocks
  3. TTI Stock
  4. TTIPF Stock
  5. Valuation Thiogenesis Therapeutics, Corp.